Focal and segmental glomerulosclerosis post COVID-19 vaccine

Descripción del Articulo

The vaccine against SARS-CoV-2 has demonstrated proven efficacy to control the disease, rare adverse effects due to this therapy are still being studied, some of them renal. It is suggested that an inadequate immune response could be the cause of glomerular diseases associated with vaccination. We d...

Descripción completa

Detalles Bibliográficos
Autores: Arellan-Bravo, Luis, León-Gonzales, Robert, Chávez-Bustamante, Sarai G., Cerrón Ventocilla, Katterine Jhanet, Asato-Higa, Carmen
Formato: artículo
Fecha de Publicación:2023
Institución:Universidad Nacional Mayor de San Marcos
Repositorio:Revistas - Universidad Nacional Mayor de San Marcos
Lenguaje:español
OAI Identifier:oai:ojs.csi.unmsm:article/25296
Enlace del recurso:https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/25296
Nivel de acceso:acceso abierto
Materia:Vacunas contra la COVID-19
Glomerulonefritis
Perú
Vaccines against COVID-19
Glomerulonephritis
Peru
id REVUNMSM_957dd4a18ca7dbf792cb693c043fd7ff
oai_identifier_str oai:ojs.csi.unmsm:article/25296
network_acronym_str REVUNMSM
network_name_str Revistas - Universidad Nacional Mayor de San Marcos
repository_id_str
dc.title.none.fl_str_mv Focal and segmental glomerulosclerosis post COVID-19 vaccine
Glomeruloesclerosis focal y segmentaria post vacuna COVID-19
title Focal and segmental glomerulosclerosis post COVID-19 vaccine
spellingShingle Focal and segmental glomerulosclerosis post COVID-19 vaccine
Arellan-Bravo, Luis
Vacunas contra la COVID-19
Glomerulonefritis
Perú
Vaccines against COVID-19
Glomerulonephritis
Peru
title_short Focal and segmental glomerulosclerosis post COVID-19 vaccine
title_full Focal and segmental glomerulosclerosis post COVID-19 vaccine
title_fullStr Focal and segmental glomerulosclerosis post COVID-19 vaccine
title_full_unstemmed Focal and segmental glomerulosclerosis post COVID-19 vaccine
title_sort Focal and segmental glomerulosclerosis post COVID-19 vaccine
dc.creator.none.fl_str_mv Arellan-Bravo, Luis
León-Gonzales, Robert
Chávez-Bustamante, Sarai G.
Cerrón Ventocilla, Katterine Jhanet
Asato-Higa, Carmen
Arellan-Bravo, Luis
León-Gonzales, Robert
Chávez-Bustamante, Sarai G.
Cerrón Ventocilla, Katterine Jhanet
Asato-Higa, Carmen
author Arellan-Bravo, Luis
author_facet Arellan-Bravo, Luis
León-Gonzales, Robert
Chávez-Bustamante, Sarai G.
Cerrón Ventocilla, Katterine Jhanet
Asato-Higa, Carmen
author_role author
author2 León-Gonzales, Robert
Chávez-Bustamante, Sarai G.
Cerrón Ventocilla, Katterine Jhanet
Asato-Higa, Carmen
author2_role author
author
author
author
dc.subject.none.fl_str_mv Vacunas contra la COVID-19
Glomerulonefritis
Perú
Vaccines against COVID-19
Glomerulonephritis
Peru
topic Vacunas contra la COVID-19
Glomerulonefritis
Perú
Vaccines against COVID-19
Glomerulonephritis
Peru
description The vaccine against SARS-CoV-2 has demonstrated proven efficacy to control the disease, rare adverse effects due to this therapy are still being studied, some of them renal. It is suggested that an inadequate immune response could be the cause of glomerular diseases associated with vaccination. We describe a 26-year-old patient, with no significant history, received immunity from the SARS-CoV-2 vaccine (Sinopharm), after which he began with proteinuria in the nephrotic range. Proteinuria: 24g in 24 hours. Albumin: 2.36 mg/dl. COVID-19 test negative. Renal biopsy was performed with ultrasound guidance, with anatomopathological result of Focal and Segmental Glomerulosclerosis, tip variant, observing 17 glomeruli. The patient was hospitalized and received immunosuppression with pulses of methylprednisolone, oral prednisone 1mg/kg/day, atorvastatin 20mg/day, antiplatelet therapy with ASA 100mg/day, omeprazole 20mg/day, and trimethoprim-sulfamethoxazole prophylaxis. Two weeks later, the patient had a weight loss (10 kg), the edemas decreased significantly. Four weeks after starting treatment, she presented proteinuria <500 mg/day, which at the moment is within normal values. The development of de Novo focal segmental glomerulosclerosis is possible, after administration of the SARS-CoV-2 vaccine, and that responds to the use of corticosteroids.
publishDate 2023
dc.date.none.fl_str_mv 2023-09-28
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/25296
10.15381/anales.v84i3.25296
url https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/25296
identifier_str_mv 10.15381/anales.v84i3.25296
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/25296/20026
dc.rights.none.fl_str_mv Derechos de autor 2023 Anales de la Facultad de Medicina
http://creativecommons.org/licenses/by-nc-sa/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2023 Anales de la Facultad de Medicina
http://creativecommons.org/licenses/by-nc-sa/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana
publisher.none.fl_str_mv Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana
dc.source.none.fl_str_mv Anales de la Facultad de Medicina; Vol. 84 No. 3 (2023); 307-310
Anales de la Facultad de Medicina; Vol. 84 Núm. 3 (2023); 307-310
1609-9419
1025-5583
reponame:Revistas - Universidad Nacional Mayor de San Marcos
instname:Universidad Nacional Mayor de San Marcos
instacron:UNMSM
instname_str Universidad Nacional Mayor de San Marcos
instacron_str UNMSM
institution UNMSM
reponame_str Revistas - Universidad Nacional Mayor de San Marcos
collection Revistas - Universidad Nacional Mayor de San Marcos
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1795238260084047872
spelling Focal and segmental glomerulosclerosis post COVID-19 vaccineGlomeruloesclerosis focal y segmentaria post vacuna COVID-19Arellan-Bravo, LuisLeón-Gonzales, RobertChávez-Bustamante, Sarai G.Cerrón Ventocilla, Katterine JhanetAsato-Higa, CarmenArellan-Bravo, LuisLeón-Gonzales, RobertChávez-Bustamante, Sarai G.Cerrón Ventocilla, Katterine JhanetAsato-Higa, CarmenVacunas contra la COVID-19GlomerulonefritisPerúVaccines against COVID-19GlomerulonephritisPeruThe vaccine against SARS-CoV-2 has demonstrated proven efficacy to control the disease, rare adverse effects due to this therapy are still being studied, some of them renal. It is suggested that an inadequate immune response could be the cause of glomerular diseases associated with vaccination. We describe a 26-year-old patient, with no significant history, received immunity from the SARS-CoV-2 vaccine (Sinopharm), after which he began with proteinuria in the nephrotic range. Proteinuria: 24g in 24 hours. Albumin: 2.36 mg/dl. COVID-19 test negative. Renal biopsy was performed with ultrasound guidance, with anatomopathological result of Focal and Segmental Glomerulosclerosis, tip variant, observing 17 glomeruli. The patient was hospitalized and received immunosuppression with pulses of methylprednisolone, oral prednisone 1mg/kg/day, atorvastatin 20mg/day, antiplatelet therapy with ASA 100mg/day, omeprazole 20mg/day, and trimethoprim-sulfamethoxazole prophylaxis. Two weeks later, the patient had a weight loss (10 kg), the edemas decreased significantly. Four weeks after starting treatment, she presented proteinuria <500 mg/day, which at the moment is within normal values. The development of de Novo focal segmental glomerulosclerosis is possible, after administration of the SARS-CoV-2 vaccine, and that responds to the use of corticosteroids.La vacuna contra el SARS-CoV-2 ha demostrado eficacia comprobada para el control de la enfermedad, sin embargo, aún se encuentra en estudio los efectos adversos no comunes debido a esta terapia, algunos de tipo renal. Se plantea que una respuesta inmunológica no adecuada podría ser la causa de enfermedades glomerulares asociada a la vaEcunación. Se reporta el caso de una paciente de 26 años, sin antecedentes de importancia, recibió la inmunidad por la vacuna de SARS-CoV-2 (Sinopharm), posterior a ello inició con proteinuria en rango nefrótico (proteinuria: 24gr en 24 horas), además tuvo albúmina de 2,36 mg/dL y tuvo prueba COVID-19 negativo. Se le realizó biopsia renal con guía ecográfica, con resultado anatomo-patológico de glomeruloesclerosis focal y segmentaria, variante de punta, observándose 17 glomérulos. La paciente fue hospitalizada y recibió inmunosupresión con pulsos de metilprednisolona, prednisona vía oral (1mg/kg/día), atorvastatina (20mg/día), antiagregación plaquetaria con AAS (100mg/día), omeprazol (20mg/día) y profilaxis con trimetoprima-sulfametoxazol. Dos semanas después, la paciente, tuvo una baja de peso (10 kg) y los edemas disminuyeron notoriamente. Cuatro semanas de iniciar el tratamiento, presentó proteinuria < 500 mg/día, la cual al momento se encuentra en valores normales. Es posible el desarrollo de una glomeruloesclerosis focal y segmentaria de novo, tras la administración de la vacuna contra el SARS-CoV-2, y que respondió al uso de corticoides.Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana2023-09-28info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/2529610.15381/anales.v84i3.25296Anales de la Facultad de Medicina; Vol. 84 No. 3 (2023); 307-310Anales de la Facultad de Medicina; Vol. 84 Núm. 3 (2023); 307-3101609-94191025-5583reponame:Revistas - Universidad Nacional Mayor de San Marcosinstname:Universidad Nacional Mayor de San Marcosinstacron:UNMSMspahttps://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/25296/20026Derechos de autor 2023 Anales de la Facultad de Medicinahttp://creativecommons.org/licenses/by-nc-sa/4.0info:eu-repo/semantics/openAccessoai:ojs.csi.unmsm:article/252962023-10-07T22:29:22Z
score 13.871978
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).